U.S. markets close in 46 minutes
  • S&P 500

    4,419.50
    +7.71 (+0.17%)
     
  • Dow 30

    35,125.49
    +63.94 (+0.18%)
     
  • Nasdaq

    14,840.77
    +3.78 (+0.03%)
     
  • Russell 2000

    2,212.95
    +3.30 (+0.15%)
     
  • Crude Oil

    72.11
    +0.04 (+0.06%)
     
  • Gold

    1,796.70
    -5.10 (-0.28%)
     
  • Silver

    25.25
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1808
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3814
    +0.0060 (+0.43%)
     
  • USD/JPY

    110.3690
    -0.1410 (-0.13%)
     
  • BTC-USD

    40,089.74
    +5,816.82 (+16.97%)
     
  • CMC Crypto 200

    951.03
    +35.54 (+3.88%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

FDA eases worries regarding certain diabetes medications, AP says

The federal Food and Drug Administration and its European counterpart started reviews last year of diabetes drugs which include Merck's (MRK) Januvia and Janumet, Novo Nordisk's (NVO) Victoza and Bristol-Myers Squibb's (BMY) Byetta and Bydureon, reported the Associated Press. Both U.S. and European regulators have found no evidence of a link between these drugs and pancreas problems or pancreatic cancer.